Denali Therapeutics Inc 宣布,公司将基于其Transportvehicle技术平台,持续推进Dnl593的临床开发计划。这一决策凸显了公司对该技术路径的信心,以及其在神经疾病治疗领域的战略布局。
Denali Therapeutics Inc 宣布,公司将基于其Transportvehicle技术平台,持续推进Dnl593的临床开发计划。这一决策凸显了公司对该技术路径的信心,以及其在神经疾病治疗领域的战略布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.